ClinicalTrials.gg
Active, not recruitingNCT05873803Updated Sep 25, 2024

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

A Phase 2 interventional study of GR1802 injection and placebo in Chronic Rhinosinusitis with Nasal Polyps, sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (part of Chongqing Genrix Biopharmaceutical Co., Ltd) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Feb 2023, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Planned enrollment
26th of 43
70 · median 90
Started
2023
with 5 others
Phase 2
13 of 46
4 open now
Primary completion
2024-10
later than 1 of 23 live
Registered
20th of 46
by date
Lead sponsor
2 of 46
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Among the 46 studies in Nasal Polyps with a site in China, this one is the 26th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 1 of the 23 other live ones, and was the 20th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients will receive GR1802 injection or Placebo every 2 Weeks.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the preliminary efficacy and safety of GR1802 injection in patients with chronic rhinosinusitis with nasal polyps.

The study consists of a Screening/run-in Period (up to 4 weeks), a Randomized, Double Blind Treatment Period (16 weeks) and a Safety Follow-up Period (8 weeks).

70 subjects will be randomized 1:1 into the 300 mg first dose doubling Q2W group and the placebo Q2W group. Throughout the dosing period, all subjects continued treatment with standard therapy at a stable dose.

Patient-reported outcome including Nasal congestion score will be collected using patient diary. Central reading will be implemented to Nasal endoscopic nasal polyp score (NPS) and nasal polyp biopsy tissue analysis to eosinophil counts \& percentage.

03

Conditions studied

  • Chronic Rhinosinusitis with Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Bilateral CRSwNP with prior treatment with systemic (SCS), and/or contraindicate to or intolerance to SCS, and/or with prior surgery to nasal polyps
  2. Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity at screening and at baseline.
  3. Ongoing symptoms of nasal congestion/obstruction(NCS score of 2 or 3 at screening and at baseline).
  4. Recorded use of intranasal corticosteroids for at least 4 weeks before screening

Exclusion criteria

Exclusion Criteria:

  1. Insufficient washout time for drugs that have an impact on the evaluation of efficacy and safety。
  2. Concurrent disease that may interfere with the evaluation of safety and efficacy in subjects, or affect the risk- benefit evaluation of subjects. eg. specific ongoing nasal diseases, severe asthma, active infection, Severe cardiovascular disease, Severe laboratory test abnormalities.
  3. Other.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Experimental: GR1802

    GR1802 injection 300mg every two weeks for 16-week treatment

    Biological: GR1802 injection

  • Placebo comparator
    Placebo Comparator: Placebo

    Placebo every two weeks for 16-week treatment

    Biological: placebo

Interventions

  • 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

  • Biologicalplacebo

    0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 16 in Nasal Congestion/Obstruction Symptom(NCS) Severity Score

    Change from baseline in the NCS score. NCS score (0-3), higher score means worse nasal symptom.

    Time frame: at Week 16

  2. Change From Baseline at Week 16 in Nasal Polyp Score

    NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: at Week 16

Secondary outcomes

  1. Time to the first response of NPS

    Time to the first response of NPS (defined as bilateral endoscopic NPS improved ≥1).

    Time frame: Baseline up to Week 24

  2. Lund-Mackay score

    Change from baseline in the Lund-Mackay score on CT scan. The range of LM score is 0-24. Higher score means worse rhinosinusitis.

    Time frame: at Week 16

  3. Bilateral endoscopic NPS

    Change from baseline in the bilateral endoscopic NPS at Week 4, 8, 12, 24.

    Time frame: at Week 4, 8, 12, 24

  4. Nasal Congestion/Obstruction Symptom score(NCS)

    Change from baseline in NCS at Week 4, 8, 12, 24.

    Time frame: at Week 4, 8, 12, 24

  5. University of Pennsylvania Smell Identification Test (UPSIT)

    Change from baseline in UPSIT. UPSIT score (0-40). Higher score means better sense of smell.

    Time frame: at Week 16

  6. Total Nasal Symptom Score(TNSS) score

    Change from baseline in TNSS score. TNSS score (0-9). Higher score means worse nasal symptom.

    Time frame: at Week 16

  7. Visual Analogue Scale (VAS) for Rhinosinusitis

    Change from baseline in VAS score. VAS score (0-10). Higher score means worse nasal symptom.

    Time frame: at Week 16

  8. Proportion of subjects receiving rescue therapy for nasal polyps

    Rescue therapy includes Systemic Corticosteroids and endoscopic surgery

    Time frame: Baseline up to Week 24

  9. Pharmacokinetics(PK)

    Plasma concentration of GR1802 injection. PK parameter including trough concentration and exposure(CL/F, Vz/F etc.)

    Time frame: Baseline up to Week 24

  10. Pharmacodynamics(PD)

    Change from baseline in serum biomarker level (Periostin, TARC, total IgE and eosinophil level) and biomarkers in nasal secretions and nasal exfoliated cells。

    Time frame: at Week 16

  11. Anti-drug antibodies(ADA)

    Incidence of ADA

    Time frame: Baseline up to Week 24

  12. Safety parameters

    Incidence of treatment-emergent adverse events (TEAEs), of treatment-emergent serious AEs (TESAEs), etc.

    Time frame: Baseline up to Week 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Oct 2024, 20 months after the start.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
May 24, 2023
StartActual
Feb 8, 2023
Primary completionEst.
Oct 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05873803
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Feb 8, 2023
Primary completion
Oct 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Sep 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telikibart

Start the discussion